Inhibikase Therapeutics (IKT) Research & Development (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Research & Development of $10.8 million for Q1 2026, up 3.1% year-over-year from $10.5 million in Q1 2025, and up 70.46% quarter-over-quarter from $6.4 million in Q4 2025.
Inhibikase Therapeutics (IKT) Research & Development (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Research & Development data on file, last reported at $10.8 million in Q1 2026.
- Research & Development for Q1 2026 came in at $10.8 million, up 3.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.1 million (up 20.61% YoY), and the FY2025 annual result was $29.8 million, up 73.11% from the prior year.
- Research & Development advanced to $10.8 million in Q1 2026 per IKT's latest filing, from $6.4 million in the prior quarter.
- Over five years, Research & Development peaked at $13.6 million in Q4 2023 and troughed at $2.8 million in Q1 2024.
- A 5-year average of $5.5 million and a median of $4.2 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development jumped 344.91% in 2023, then plunged 47.06% in 2024.
- A 5-year view of Research & Development shows it stood at $3.1 million in 2022, then soared by 344.91% to $13.6 million in 2023, then sank by 47.06% to $7.2 million in 2024, then declined by 11.6% to $6.4 million in 2025, then surged by 70.46% to $10.8 million in 2026.
- Business Quant data shows IKT's Research & Development at $10.8 million in Q1 2026, $6.4 million in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -58.00 Mn |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | 10.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.84 Mn |
| Dec 31, 2025 | 6.36 Mn |
| Sep 30, 2025 | 7.65 Mn |
| Jun 30, 2025 | 5.27 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Dec 31, 2024 | 7.19 Mn |
| Sep 30, 2024 | 4.19 Mn |
| Jun 30, 2024 | 3.08 Mn |
| Mar 31, 2024 | 2.75 Mn |
| Dec 31, 2023 | 13.59 Mn |
| Sep 30, 2023 | 3.23 Mn |
| Jun 30, 2023 | 4.54 Mn |
| Mar 31, 2023 | 2.85 Mn |
| Dec 31, 2022 | 3.05 Mn |
| Sep 30, 2022 | 2.98 Mn |
| Jun 30, 2022 | 2.98 Mn |
| Mar 31, 2022 | 3.02 Mn |
| Dec 31, 2021 | 3.39 Mn |
| Sep 30, 2021 | 3.15 Mn |
| Jun 30, 2021 | 2.38 Mn |